Company Overview and News

Toyo Ink looks to a better FY19

2018-09-07 theedgemarkets
KUALA LUMPUR: Toyo Ink Group Bhd is looking forward to achieve a better performance in its financial year ending March 31, 2019 (FY19) compared with FY18, given that the group has disposed of some of its businesses that were underperforming.

KLCI remains in the red, down 0.52% in line with region

2018-09-05 theedgemarkets
KUALA LUMPUR (Sept 5): The FBM KLCI remained in the red at mid-morning and was down 0.52%, in line with the weaker regional markets.
HLFBF APEXF 7173 PBLOF 7090 4065 7036 1082 BATS 4162 0162 1295 8311 6033 PNADF 0104 2216 5819 PNAGF 3719

KLCI seen drifting lower, immediate support at 1,760

2018-08-02 theedgemarkets
KUALA LUMPUR (Aug 3): The FBM KLCI is seen drifting lower Friday tracking the overnight losses at mot global markets on worries of an escalation in the trade dispute between the U.S. and China, with immediate support at 1,760.
0176 7173 AAPL 7158

Toyo Ink plans one-for-two free warrants

2018-08-02 theedgemarkets
KUALA LUMPUR (Aug 2): Toyo Ink Group Bhd plans to issue one free warrant for every two shares of the group that are held at an entitlement date to be fixed to reward shareholders.

F&N, Omesti, Toyo Ink, Kronologi Asia, Scomi Group and Unisem

2018-08-02 theedgemarkets
KUALA LUMPUR (Aug 2): Based on corporate announcements and news flow today, companies in focus on Friday (Aug 3) may include: Fraser & Neave Holdings Bhd (F&N), Omesti Bhd, Toyo Ink Group Bhd, Kronologi Asia Bhd, Scomi Group Bhd and Unisem (M) Bhd.
0176 7173 7366 7158 7045

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...